Trial Profile
A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy (FALCON)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Anastrozole
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms FALCON
- Sponsors AstraZeneca
- 08 Feb 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 24 Oct 2023 Results assessing prespecified final analysis of overall survival, presented at the 48th European Society for Medical Oncology Congress.
- 25 Sep 2023 This trial has been completed in Spain, according to European Clinical Trials Database record.